- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02126553
Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission
Phase II Study of Lenalidomide Maintenance in Patients With High Risk AML in Remission
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To assess relapse-free survival (RFS) of patients with acute myeloid leukemia (AML) treated with lenalidomide maintenance therapy after achieving remission.
SECONDARY OBJECTIVES:
I. To assess overall survival (OS) of patients with AML treated with lenalidomide maintenance.
II. To assess event-free survival (EFS) of patients with AML treated with lenalidomide maintenance.
III. To assess the duration of remission (CRd) of patients with AML treated with lenalidomide maintenance.
IV. To assess toxicity and safety of lenalidomide maintenance in patients with AML.
V. To assess the effects of lenalidomide maintenance on natural killer (NK) cell modulation and dynamics of minimal residual disease and their relationship to outcomes.
OUTLINE:
Patients receive lenalidomide orally (PO) once daily (QD) on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6-12 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients aged 18 to 55 years with high risk AML who have achieved their FIRST complete remission (CR) or complete remission with incomplete recovery (CRi) within 12 months of enrollment and are not immediately candidates for allogeneic stem cell transplant; patients above age 55 who are not eligible for other protocols may be considered for enrollment on a case by case basis after discussion with the principal investigator (PI)
- Patients in their FIRST CR or CRi may be eligible for enrollment only if they have a high risk feature, including, but not limited to: adverse karyotype, fms-related tyrosine kinase 3 (FLT3) mutation, history of antecedent hematologic disorder (AHD), presence of dysplasia in the bone marrow, therapy-related AML, history of requiring more than 1 cycle of intensive induction chemotherapy to achieve first remission, or presence of persistent minimal residual disease (detected by cytogenetics, molecular markers, or flow cytometry) at any point after initial induction cycle; patients aged >= 18 years with AML who have achieved a SECOND CR or CRi within 12 months of enrollment and are not immediately candidates for allogeneic stem cell transplant are also eligible
- Patients should have received induction chemotherapy for AML and at least 1 consolidation
- Patients with history of extramedullary AML, except for central nervous system (CNS) involvement that is currently controlled, will not be eligible for enrollment
- Eastern Cooperative Oncology Group (ECOG) performance status of < or = 3
- Serum total bilirubin < or = to 1.5 X the upper limit of normal (ULN)
- Serum creatinine < or = to 2.5 x ULN
- Absolute neutrophil count (ANC) > 0.5 x 10^9/L
- Platelet count > or = 30 x 10^9/L
- For females of childbearing age, they may participate it they: a. have a negative serum or urine pregnancy test within 10 to 14 days of enrolling (a second pregnancy test will be performed within 24 hours (hrs) of starting therapy and both negative pregnancy tests will be required for starting therapy); b. agree to either abstinence or 2 effective contraceptive methods throughout the treatment period and up to 28 days after discontinuing treatment
- For male patients with a female partner of childbearing age, they may participate if they agree to either abstinence or 2 effective contraceptive methods throughout the treatment period and up to 28 days after discontinuing treatment
- All study participants be willing and able to comply with the requirements of the Risk Evaluation and Mitigation Strategies (REMS) program
- Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
- Ability to understand and sign informed consent
Exclusion Criteria:
- Diagnosis of acute promyelocytic leukemia (APL), AML - M3 by French American British (FAB) classification based on morphology, immunophenotype, molecular, or cytogenetics studies
- Diagnosis of AML associated with the following karyotypes: inversion (inv)(16), t(16;16), t(8;21), t(15;17), or t(9;22)
- Uncontrolled intercurrent illness including, but not limited to ongoing or active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Previous treatment with lenalidomide for AML
- Patients with documented hypersensitivity to any components of the study program
- Females who are pregnant
- Patients with active CNS disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (lenalidomide)
Patients receive lenalidomide PO QD on days 1-28.
Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relapse-free Survival (RFS)
Time Frame: Up to 7 Years
|
Time from date of treatment start until the date of first objective documentation of disease-relapse.
|
Up to 7 Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: Up to 7 Years
|
Time from date of treatment start until date of death due to any cause or last Follow-up.
Survival will be measured by the estimated median survival computed by Kaplan-Meier (K-M) analysis, which is the time point at which the cumulative survival drops below 50%, if present.
If not present then the median Overall Survival is not reached and not available (NA) as there are an insufficient number of participants with events.
In either case ranges are provided for observed survival intervals used in the K-M analysis.
|
Up to 7 Years
|
Event-free Survival (EFS)
Time Frame: Up to 7 Years
|
Time from date of treatment start until the date of first objective documentation of disease-relapse, death or discontinuation due to adverse events.
|
Up to 7 Years
|
Complete Response (CR) Duration
Time Frame: Up to 7 years
|
Complete Response is defined as disappearance of all clinical and/or radiologic evidence of disease, including extramedullary leukemia.
Neutrophil count >/= 1.0 x 10^9/L and platelet count>/= 100 x 10^9, and bone marrow differential showing </=5%blasts.
Response date to loss of response or last follow up.
Remission duration will be measured by the estimated median remission duration computed by Kaplan-Meier (K-M) analysis, which is the time point at which the cumulative remission duration drops below 50%, if present.
If not present then median remission duration is not reached and not available (NA) as there are an insufficient number of participants with events.
In either case ranges are provided for observed survival intervals used in the K-M analysis.
|
Up to 7 years
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014-0116 (M D Anderson Cancer Center)
- NCI-2014-01176 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Secondary Acute Myeloid Leukemia
-
The First Affiliated Hospital with Nanjing Medical...RecruitingSecondary Acute Myeloid LeukemiaChina
-
Antisoma ResearchUnknownSecondary Acute Myeloid Leukemia (Secondary AML, sAML)Korea, Republic of, United States, Spain, United Kingdom, Australia, Austria, Taiwan, Israel, Italy, Belgium, Germany, France, Romania, Estonia, Canada, Ukraine, Ecuador, Hungary, Poland, Chile, Argentina, Czech Republic, Russian Federation
-
M.D. Anderson Cancer CenterActive, not recruitingSecondary Acute Myeloid LeukemiaUnited States
-
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....Not yet recruitingHigh-risk (Secondary) Acute Myeloid LeukemiaChina
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Uma BorateSumitomo Pharma Oncology, Inc.CompletedAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid LeukemiaUnited States
-
University of Michigan Rogel Cancer CenterGenentech, Inc.Not yet recruitingSecondary Acute Myeloid LeukemiaUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States